| CHEN, TAO |
NCT05604859: Evaluate the Efficacy and Safety of Various Treatment Schemes for Severe Fever With Thrombocytopenia Syndrome(SFTS) |
|
|
| Recruiting | 4 | 350 | RoW | Methylprednisolone, intravenous immunoglobulin, Tocilizumab, Low molecular weight heparin, conventional treatment | Qin Ning | Severe Fever With Thrombocytopenia Syndrome | 12/23 | 06/24 | | |
NCT06103825: A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Solriamfetol in the Treatment of Excessive Daytime Sleepiness (EDS) in Patients With Obstructive Sleep Apnea (OSA) |
|
|
| Recruiting | 3 | 204 | RoW | Solriamfetol, Placebo | Ignis Therapeutics (Suzhou) Limited | Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea | 09/24 | 10/24 | | |
NCT06010693: A Study of Daridorexant in Chinese Patients With Insomnia Disorder |
|
|
| Completed | 3 | 206 | RoW | Daridorexant, Placebo | Jiangsu Simcere Pharmaceutical Co., Ltd. | Insomnia Disorder | 04/24 | 05/24 | | |
NCT06109818: Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 2 | 129 | RoW | ICP-488 Tablets, ICP-488 Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Moderate to Severe Plaque Psoriasis | 10/24 | 11/24 | | |
NCT06433531: A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP) |
|
|
| Recruiting | 1 | 10 | RoW | TQH2929 Injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Generalized Pustular Psoriasis | 02/25 | 02/25 | | |
NCT06437067: Study on Prognosis of Acute-on-chronic Liver Failure Complicated by Bacterial or Fungal Infection |
|
|
| Recruiting | N/A | 400 | RoW | | Qin Ning | Acute-On-Chronic Liver Failure | 12/24 | 06/25 | | |
NCT05440357: Second-line Pharmacotherapy Patterns and Outcomes of Advanced Gastrointestinal Stromal Tumor: A Real-world Study |
|
|
| Recruiting | N/A | 100 | RoW | | Xinhua Zhang, MD, Guangdong Provincial People's Hospital, Nanfang Hospital, Southern Medical University, Sixth Affiliated Hospital, Sun Yat-sen University, Peking University Shenzhen Hospital, Cancer Hospital of Guangxi Medical University, Hainan Cancer Hospital, The First Affiliated Hospital of Nanchang University, Second Affiliated Hospital of Nanchang University, Yunnan Cancer Hospital, Chongqing University Cancer Hospital | Gastrointestinal Stromal Tumors | 09/24 | 09/24 | | |
NCT05347901: Clinical Precise Diagnosis and Treatment in the Kawasaki Disease |
|
|
| Recruiting | N/A | 800 | RoW | Echocardiography, Genomics NGS sequencing | Affiliated Hospital of Nantong University, Children's Hospital of Fudan University Qidong Branch, Second Affiliated Hospital of Nantong University, Jiangsu Hai'an People's Hospital | Kawasaki Disease | 01/24 | 07/24 | | |
NCT06365073: A Case-control Study on the Clinical Characteristics of 28-day and 90-day Death From Severe Anthrax |
|
|
| Recruiting | N/A | 80 | RoW | | Qin Ning | Anthrax | 08/24 | 12/24 | | |
NCT04972591: Follow-up Study of Population Vaccinated With COVID-19 Vaccine |
|
|
| Recruiting | N/A | 1000 | RoW | | Qin Ning, First Affiliated Hospital Xi'an Jiaotong University, Yichang Central Hospital., First Affiliated Hospital of Wenzhou Medical University, Xiangya Hospital of Central South University, Shiyan Renmin Hospital, The second Hospital of JingZhou, Yunnan Provincial Infectious Disease Hospital, WUHAN NO.7 HOSPITAL, Shanxi Bethune Hospital | Healthy | 12/21 | 06/22 | | |
NCT05313854: Diagnosis and Survival Prediction of Pancreatic Cancer by Machine Learning of Image Data |
|
|
| Recruiting | N/A | 1000 | RoW | | RenJi Hospital | Pancreatic Cancer | 12/23 | 12/23 | | |
| ZHANG, Litao |
NCT04875169: Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis |
|
|
| Completed | 3 | 336 | Canada, RoW | Core Treatment Active Experimental: SHR0302 Dose#1, Core Treatment Active Experimental: SHR0302 Dose#2, Core Treatment Placebo Comparator: Placebo, Extension Treatment Active Experimental: SHR0302 Dose#1, Extension Treatment Active Experimental: SHR0302 Dose#2 | Reistone Biopharma Company Limited | Atopic Dermatitis | 08/22 | 05/23 | | |
NCT05470413: Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata |
|
|
| Active, not recruiting | 3 | 330 | RoW | SHR0302, Placebo | Reistone Biopharma Company Limited | Alopecia Areata | 10/23 | 02/24 | | |
NCT06587685: A Study to Assess the Efficacy and Safety of PG-011 Gel in Adolescents and Adults With Atopic Dermatitis |
|
|
| Recruiting | 3 | 472 | RoW | PG-011Gel, PG-011Gel 3%, Vehicle, placebo | Prime Gene Therapeutics Co., Ltd. | Atopic Dermatitis | 12/24 | 01/26 | | |
NCT05975268: A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis |
|
|
| Active, not recruiting | 3 | 747 | RoW | JS005 (recombinant humanized monoclonal antibody against IL-17A) | Shanghai Junshi Bioscience Co., Ltd. | Moderate to Severe Chronic Plaque Psoriasis | 08/25 | 10/25 | | |
NCT06552520: To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis |
|
|
| Not yet recruiting | 3 | 500 | RoW | TQH2722 injection, Placebo of TQH2722 injection | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Atopic Dermatitis | 10/25 | 06/26 | | |
NCT06775860: ICP-332 in Subjects with Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 552 | RoW | ICP-332 Tablets, ICP-332 Placebo Tablets | Beijing InnoCare Pharma Tech Co., Ltd. | Atopic Dermatitis | 11/26 | 12/26 | | |
MARBLE-23, NCT04717310: Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis |
|
|
| Active, not recruiting | 2/3 | 645 | RoW | SHR0302 Ointment, SHR0302 Ointment 2%, SHR0302 Ointment 1%, SHR0302 Ointment 0.5%, Vehicle, Placebo | Reistone Biopharma Company Limited | Atopic Dermatitis | 09/23 | 07/24 | | |
NCT05702268: Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 75 | RoW | ICP-332, ICP-332 Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Moderate to Severe Atopic Dermatitis | 07/23 | 12/23 | | |
NCT05970432: A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 160 | RoW | TQH2722 injection 300mg-150mg, TQH2722 injection 600mg-300mg, TQH2722 injection 900mg-450mg, TQH2722 injection matching Placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Atopic Dermatitis | 03/24 | 03/24 | | |
NCT06109818: Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 2 | 129 | RoW | ICP-488 Tablets, ICP-488 Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Moderate to Severe Plaque Psoriasis | 10/24 | 11/24 | | |
| Recruiting | 2 | 120 | RoW | TQH3906 capsules, Placebo of TQH3906 capsules | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Plaque Psoriasis | 01/25 | 09/25 | | |
NCT05999799: A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 199 | Europe, Canada, Japan, US, RoW | GSK1070806, Placebo | GlaxoSmithKline | Dermatitis, Atopic | 10/25 | 01/26 | | |
NCT06058546: Efficacy and Safety of Jiuweihuaban Pill for Treating Plaque Psoriasis |
|
|
| Recruiting | 2 | 180 | RoW | Jiuweihuaban Pill placebo, Placebo group, low dose Jiuweihuaban Pill, Low dose group, high dose Jiuweihuaban Pill, High dose group | Tasly Pharmaceutical Group Co., Ltd | Plaque Psoriasis | 10/25 | 10/25 | | |
| Wang, Hailong |
SELECT-1, NCT04397432: Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Retrospective Study |
|
|
| Active, not recruiting | N/A | 878 | RoW | | Tian Xie, LinkDoc Technology (Beijing) Co. Ltd. | Carcinoma, Non-Small-Cell Lung | 04/23 | 03/26 | | |
| Zhao, Peng |
NCT06552520: To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis |
|
|
| Not yet recruiting | 3 | 500 | RoW | TQH2722 injection, Placebo of TQH2722 injection | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Atopic Dermatitis | 10/25 | 06/26 | | |
TQ05105-III-01, NCT06682169: Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease |
|
|
| Recruiting | 3 | 182 | RoW | Rovadicitinib, Imatinib, Methotrexate, Mycophenolate mofetil, Rituximab | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Graft-versus-host Disease | 10/29 | 12/30 | | |
| Recruiting | 2 | 120 | RoW | TQH3906 capsules, Placebo of TQH3906 capsules | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Plaque Psoriasis | 01/25 | 09/25 | | |
NCT04755543: A Study of LP002 for the Treatment of Patients With Malignant Digestive System Neoplasms |
|
|
| Recruiting | 1 | 94 | RoW | LP002, Cisplatin, Fluorouracil, OH2 oncolytic virus | Taizhou HoudeAoke Biomedical Co., Ltd. | Digestive System Neoplasms | 06/21 | 06/22 | | |
| Kong, Xiang-jun |
| Recruiting | N/A | 10000 | RoW | NIS | Second Affiliated Hospital, School of Medicine, Zhejiang University | Psoriasis | 07/30 | 07/30 | | |
| Zeng, Jia |
| Recruiting | N/A | 10000 | RoW | NIS | Second Affiliated Hospital, School of Medicine, Zhejiang University | Psoriasis | 07/30 | 07/30 | | |
| Tao, Litao |
NCT06109818: Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 2 | 129 | RoW | ICP-488 Tablets, ICP-488 Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Moderate to Severe Plaque Psoriasis | 10/24 | 11/24 | | |
| Zeng, Sanwu |
NCT06552520: To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis |
|
|
| Not yet recruiting | 3 | 500 | RoW | TQH2722 injection, Placebo of TQH2722 injection | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Atopic Dermatitis | 10/25 | 06/26 | | |
